Nemes Rush Group’s Royalty Pharma RPRX Stock Holding History

Nemes Rush Group’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.12K	Hold	20	–	–	﹤0.01%	853
2026 Q1	$959	Hold	20	–	–	﹤0.01%	826
2025 Q4	$773	Buy	+20	New	+$763	﹤0.01%	841

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nemes Rush Group's RPRX Position: Q2 2026 in Review

Nemes Rush Group held its Royalty Pharma (RPRX) position steady in Q2 2026 at 20 shares worth $1.12K. The position accounts for ﹤0.01% of the portfolio, ranked #853.

Nemes Rush Group first reported a position in RPRX in Q4 2025 and has held it in 3 quarters since. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Nemes Rush Group held 20 shares of Royalty Pharma worth $1.12K as of Q2 2026.
Nemes Rush Group left its Royalty Pharma share count unchanged in Q2 2026.
Royalty Pharma made up ﹤0.01% of Nemes Rush Group's portfolio in Q2 2026, its #853 holding.
Nemes Rush Group first reported a position in Royalty Pharma in Q4 2025 and has held it in 3 quarters since.
646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Nemes Rush Group's 13F filing for Q2 2026, filed 14 Aug 2026.